Page 192 - Genentech News Today

Investegate announcements from Oxford BioDynamics, AIM Rule 17 Schedule 2(g) Update

/PRNewswire/ -- With the U.S. commercial launch of TG Therapeutics Briumvi (ublituximab-xiiy) on January 26th, 2023 for the treatment of relapsing multiple...

All proposals of the Board of Directors approvedSeverin Schwan elected as new Chairman of the Board of Directors; all other members of the Board of Directors standing for election were electedThomas Schinecker

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche Annual General Meeting 2023

An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.

Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer.

Blogs | | A 52-year-old startup CEO presented in January 2021 with distortion in the right eye. He had a large subfoveal pigment epithelial detachment but no clear subretinal fluid.

SAN ANTONIO — Patients with asthma who used a daily self-assessment with their digital inhalers reported better medication adherence, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Poor medication adherence is common among patients, and health care professionals identify poor medication adherence by objectively recording inhaler

A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.

Operator: Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call. Please note, this event is being recorded.